Abbott Laboratories (ABT)vsElutia Inc. (ELUT)
ABT
Abbott Laboratories
$107.81
-0.14%
HEALTHCARE · Cap: $182.49B
ELUT
Elutia Inc.
$0.85
-3.52%
HEALTHCARE · Cap: $38.95M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 373896% more annual revenue ($46.59B vs $12.46M). ELUT leads profitability with a 400.2% profit margin vs 11.7%. ABT earns a higher WallStSmart Score of 52/100 (C-).
ABT
Buy52
out of 100
Grade: C-
ELUT
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.2%
Fair Value
$73.84
Current Price
$107.81
$33.97 premium
Margin of Safety
+4.2%
Fair Value
$0.94
Current Price
$0.85
$0.09 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Every $100 of equity generates 221 in profit
Keeps 400 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 400.2% and operating margin at -184.4%.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Free Cash Flow.
Key Dynamics to Monitor
ABT profiles as a value stock while ELUT is a mature play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.88 — expect wider price swings.
ABT is growing revenue faster at 13.0% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
ABT scores higher overall (52/100 vs 41/100) and 13.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?